Challenges in diagnosis and management of acquired factor V inhibitors

Inhibitors to factor V is a rare phenomenon with varied clinical presentation ranging from asymptomatic states to life-threatening bleeds. They are known to be associated with exposure to bovine thrombin, drugs, autoimmune diseases and malignancies. Establishing the diagnosis of FV inhibitors is challenging and the presence of lupus-like properties of the inhibitor can further complicate the diagnosis. Here we document an unusual case of an asymptomatic elderly female posted for pacemaker implantation and incidentally, the laboratory workup revealed a disproportionately abnormal coagulation screen. The intricacies in the diagnosis and management are discussed along with a brief review of the literature. An awareness of the diverse manifestations of this underrecognized disorder and difficulties in management is essential for medical practitioners, particularly in patients with idiopathic severe bleeding diathesis.

Carbohydrates and polyphenolics of extracts from genetically altered plant acts as catalysts for in vitro synthesis of silver nanoparticle

Eco-friendly biosynthetic approach for silver nanoparticles production using plant extracts is an exciting advancement inbio-nanotechnology and has been successfully attempted in nearly 41 plant species. However, an established model plantsystem for systematically unraveling the biochemical components required for silver nanoparticles production is lacking.Here we used Arabidopsis thaliana as the model plant for silver nanoparticles biosynthesis in vitro. Employing biochemical, spectroscopic methods, selected mutants and over-expressor plants of Arabidopsis involved in pleotropicfunctions and sugar homeostasis, we show that carbohydrates, polyphenolics and glyco-proteins are essential componentswhich stimulated silver nanoparticles synthesis. Using molecular genetics as a tool, our data enforces the requirement ofsugar conjugated proteins as essentials for AgNPs synthesis over protein alone. Additionally, a comparative analysis ofAgNPs synthesis using the aqueous extracts of some of the plant species found in a brackish water ecosystem (Gracilaria,Potamogeton, Enteromorpha and Scendesmus) were explored. Plant extract of Potamogeton showed the highest potentialof nanoparticles production comparable to that of Arabidopsis among the species tested. Silver nanoparticles production inthe model plant Arabidopsis not only opens up a possibility of using molecular genetics tool to understand the biochemicalpathways and components in detail for its synthesis.

The role of melatonin in diabetes: therapeutic implications

Melatonin referred as the hormone of darkness is mainly secreted by pineal gland, its levels being elevated during night and low during the day. The effects of melatonin on insulin secretion are mediated through the melatonin receptors (MT1 and MT2). It decreases insulin secretion by inhibiting cAMP and cGMP pathways but activates the phospholipaseC/IP3 pathway, which mobilizes Ca2+from organelles and, consequently increases insulin secretion. Both in vivo and in vitro, insulin secretion by the pancreatic islets in a circadian manner, is due to the melatonin action on the melatonin receptors inducing a phase shift in the cells. Melatonin may be involved in the genesis of diabetes as a reduction in melatonin levels and a functional interrelationship between melatonin and insulin was observed in diabetic patients. Evidences from experimental studies proved that melatonin induces production of insulin growth factor and promotes insulin receptor tyrosine phosphorylation. The disturbance of internal circadian system induces glucose intolerance and insulin resistance, which could be restored by melatonin supplementation. Therefore, the presence of melatonin receptors on human pancreatic islets may have an impact on pharmacotherapy of type 2 diabetes.

Monoclonal antibody conjugated Nanoparticles targeted to Prostate tumor cells.

Novel approaches to drug delivery and formulation using nanotechnology are revolutionizing the future of medicine. The application of nanotechnology in medicine is offering many exciting possibilities in healthcare. Engineered nanoparticles and conjugation of monoclonal antibodies with anticancer drug Docetaxel have the potential to revolutionize the diagnosis and the therapy of its diseases, particularly by targeted delivery of anticancer drugs and imaging contrast agents. Prostate cancer, the second most common cancer in men, represents one of the major epidemiological problems, especially for patients in the advanced age. There is a substantial interest in developing therapeutic options for treatment of prostate cancer based on use of nanocarriers with the conjugation of drug and antibody, to overcome the lack of specificity of conventional chemotherapeutic agents as well as for the early detection of precancerous and malignant lesions. In this article, we highlight on the recent development of bioconjugation of drug with nanotechnology strategies adopted for the management of prostate cancer. In particular, the combination of targeted and controlled-release polymer nanocarriers have worked against prostate specific membrane antigen, a promising targeted Docetaxel-loaded nanoparticles, which can be validated for use in the prostate cancer therapy. However, several limitations facing nanoparticle delivery to solid tumors, such as heterogeneity of intratumoural barriers and vasculature, cytotoxicity and or hypersensitivity reactions to currently available cancer nanomedicines, and the difficult in developing targeted nanoparticles with optimal biophysicochemical properties, should be still addressed for successful tumor eradication.